Researchers who used the company's service presented data this week from analyses of sarcoma patients that they believe can help personalize care.
Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.
In Cell this week: integrated genomic analysis of adult soft tissue sarcoma, positive selection has greater role in cancer than negative selection, and more.
Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
An epigenetic analysis showed that the tumors all shared a certain DNA methylation signature, but that methylation patterns varied between samples.
The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.
Rare germline mutations in cancer risk genes turned up in more than half of sarcoma patients tested by gene panel sequencing.
The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.
An analysis of angiosarcoma-derived cell lines identified a NUP160-SLC43A3 fusion that subsequently turned up in aggressive primary tumor samples.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.